email article Men with poor-prognosis metastatic castration-resistant prostate cancer (mCRPC) had better outcomes with cabazitaxel (Cabometyx) as initial therapy instead of an androgen-receptor inhibitor, a phase II randomized trial showed. First-line taxane therapy led to a clinical benefit rate (CBR, response plus stable disease) of 80% as compared with 62% for patients treated with either enzalutamide (Xtandi) or abiraterone (Zytiga). Patients treated with cabazitaxel lived more than twice as long, although the difference did not reach statistical significance because of a small patient population. Patients treated with cabazitaxel had higher rates of grade ≥3 neutropenia, diarrhea, and infection, reported Kim N. Chi, MD, of BC Cancer in Vancouver, and colleagues, in